argenex SE $ARGX Holdings Boosted by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. lifted its stake in shares of argenex SE (NASDAQ:ARGX) by 15.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,338 shares of the company’s stock after purchasing an additional 696 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in argenex were worth $5,181,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ARGX. Janus Henderson Group PLC boosted its stake in argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after purchasing an additional 83,568 shares during the period. Jennison Associates LLC grew its holdings in argenex by 3.4% during the 1st quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock valued at $173,411,000 after buying an additional 7,707 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in argenex by 1.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock valued at $130,277,000 after buying an additional 2,579 shares in the last quarter. First Trust Advisors LP increased its position in shares of argenex by 98.9% during the first quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock valued at $78,279,000 after buying an additional 53,293 shares during the period. Finally, Eagle Health Investments LP increased its position in shares of argenex by 21.7% during the first quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock valued at $55,744,000 after buying an additional 13,606 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ARGX shares. Truist Financial increased their price target on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. HC Wainwright boosted their price objective on shares of argenex from $940.00 to $1,202.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. UBS Group raised shares of argenex from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. Piper Sandler upped their target price on shares of argenex from $1,075.00 to $1,215.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Finally, Guggenheim lowered their target price on shares of argenex from $1,185.00 to $1,120.00 and set a “buy” rating on the stock in a research note on Friday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,145.00.

argenex Stock Up 0.7%

NASDAQ:ARGX opened at $897.85 on Friday. The stock has a market cap of $56.46 billion, a P/E ratio of 31.33, a PEG ratio of 0.82 and a beta of 0.44. The business’s 50-day moving average price is $946.51 and its two-hundred day moving average price is $854.33. argenex SE has a twelve month low of $661.85 and a twelve month high of $1,072.75.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping the consensus estimate of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The company had revenue of $1.75 billion during the quarter. On average, equities research analysts expect that argenex SE will post 28.63 EPS for the current fiscal year.

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.